Prosight Management’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.4M Buy
+550,700
New +$12.9M 2.21% 15

Other funds holding DNLI

Prosight Management's DNLI Position: Q3 2026 in Review

Prosight Management opened a new position in Denali Therapeutics (DNLI) in Q3 2026: 550,700 shares worth $11.4M. The stake represents 2.21% of the portfolio and ranks #15 among its holdings.

287 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

  • Prosight Management held 550,700 shares of Denali Therapeutics worth $11.4M as of Q3 2026.
  • Denali Therapeutics was a new Prosight Management position in Q3 2026.
  • Denali Therapeutics made up 2.21% of Prosight Management's portfolio in Q3 2026, its #15 holding.
  • 287 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on Prosight Management's 13F filing for Q3 2026, filed 13 Nov 2026.